|
MENTAL RETARDATION, X-LINKED 99
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
De Novo Loss-of-Function Mutations in USP9X Cause a Female-Specific Recognizable Syndrome with Developmental Delay and Congenital Malformations.
|
26833328 |
2016 |
|
MENTAL RETARDATION, X-LINKED 99
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
De Novo Loss-of-Function Mutations in USP9X Cause a Female-Specific Recognizable Syndrome with Developmental Delay and Congenital Malformations.
|
26833328 |
2016 |
|
MENTAL RETARDATION, X-LINKED 99, SYNDROMIC, FEMALE-RESTRICTED
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
De Novo Loss-of-Function Mutations in USP9X Cause a Female-Specific Recognizable Syndrome with Developmental Delay and Congenital Malformations.
|
26833328 |
2016 |
|
MENTAL RETARDATION, X-LINKED 99, SYNDROMIC, FEMALE-RESTRICTED
|
0.700 |
GermlineCausalMutation
|
disease |
ORPHANET |
De Novo Loss-of-Function Mutations in USP9X Cause a Female-Specific Recognizable Syndrome with Developmental Delay and Congenital Malformations.
|
26833328 |
2016 |
|
MENTAL RETARDATION, X-LINKED 99
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Mutations in USP9X are associated with X-linked intellectual disability and disrupt neuronal cell migration and growth.
|
24607389 |
2014 |
|
MENTAL RETARDATION, X-LINKED 99
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Mutations in USP9X are associated with X-linked intellectual disability and disrupt neuronal cell migration and growth.
|
24607389 |
2014 |
|
MENTAL RETARDATION, X-LINKED 99, SYNDROMIC, FEMALE-RESTRICTED
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Mutations in USP9X are associated with X-linked intellectual disability and disrupt neuronal cell migration and growth.
|
24607389 |
2014 |
|
MENTAL RETARDATION, X-LINKED 99
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
MENTAL RETARDATION, X-LINKED 99
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
|
MENTAL RETARDATION, X-LINKED 99
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
MENTAL RETARDATION, X-LINKED 99, SYNDROMIC, FEMALE-RESTRICTED
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
MENTAL RETARDATION, X-LINKED 99, SYNDROMIC, FEMALE-RESTRICTED
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
|
MENTAL RETARDATION, X-LINKED 99, SYNDROMIC, FEMALE-RESTRICTED
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Polydactyly
|
0.300 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
De Novo Loss-of-Function Mutations in USP9X Cause a Female-Specific Recognizable Syndrome with Developmental Delay and Congenital Malformations.
|
26833328 |
2016 |
|
Mental Retardation, X-Linked 1
|
0.300 |
GermlineCausalMutation
|
disease |
ORPHANET |
Mutations in USP9X are associated with X-linked intellectual disability and disrupt neuronal cell migration and growth.
|
24607389 |
2014 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
RESULTS Immunohistochemistry showed that USP9X was significantly overexpressed in 93 of 102 (91.1%) breast cancer tissue samples compared with 41 normal breast tissue samples and was associated with tumor size ≥5.0 cm (P<0.05).
|
31169265 |
2019 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
USP9X is highly expressed in a number of tissue types and acts as both an oncogene and tumor suppressor in several human cancers.
|
30767316 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The deubiquitinase USP9X is involved in multiple diseases including neurodegeneration, epilepsy, and various types of tumors by targeting different substrates.
|
31059266 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Furthermore, in vivo biodistribution indicates that Fe-MOF-5-NH2-FA-5-FAM/5-FU can accumulate in the tumor.
|
31714562 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In addition, Usp9x inactivation impaired intestinal regeneration and increased tumor burden in colitis-associated intestinal cancer. c-Myc heterozygosity abrogated increased progenitor proliferation and tumor burden in Usp9x-deficient mice, suggesting that Usp9x suppresses tumor formation by regulating Fbw7 protein stability and thereby reducing c-Myc.
|
29346117 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Usp9x inhibition by shRNA-knockdown or by G9 treatment reduced 3D colony formation in PANC1 and PDX cell lines, induced rapid apoptosis in MIAPACA2 cells, and associated with reduced Mcl-1 and ITCH protein levels.
|
29248719 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The deubiquitinase USP9X promotes tumor cell survival and confers chemoresistance through YAP1 stabilization.
|
29449692 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
However, the molecular mechanism for USP9X regulation of tumor cell survival and tumorigenesis in NSCLC is less defined.
|
29721084 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The results of the present study indicate that USP9X may serve as a candidate tumor suppressor and prognostic biomarker in PDAC.
|
29844826 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Moreover, the in vivo biodistribution and antitumor assays indicate that UIO-66-NH2-FA-5-FAM/5-FU can accumulate in the tumor and display stronger antitumor efficiency due to the long-time drug release.
|
29560986 |
2018 |